With continued pressure on drug development timelines paired with a lack of regulatory guidance, the demand for innovative, efficient, and high-throughput analytical methods is crucial to ensure the approval and successful commercialisation of safe and effective mRNA therapeutics and vaccines.

As such, the highly anticipated 2nd mRNA Analytical Development Summit Europe 2024 returned to Berlin as the premier gathering for industry professionals to delve into optimised mRNA analytics. Our attendees joined us to gain critical expertise and hear the latest techniques adopted by Europe's leading biopharma leaders.

Reuniting 60+ industry experts in Analytical Development, Quality Control, Quality Assurance, CMC, and Regulatory, this forum aimed to tackle pivotal challenges within mRNA analytical development including biophysical characterisation, dsRNA, and tail sequence analysis. We also tackled issues related to analytical techniques to meet CQAs and CPIs for efficient and expeditious approval, as well as hurdles related to improved stability and effective delivery systems for large-scale productions to improve tissue-specific delivery.

Across this comprehensive 2-day forum, we fostered a collaborative community of like-minded experts from across Europe.